Full Press Release Details
Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer's Disease Prior to
Data Focused on Biomarkers of Neuroinflammation
will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time
LA JOLLA, Calif., July 09, 2020 (GLOBE
NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company
focused on developing treatments that harness the patient's innate immune system to fight disease, announced that next
week it will report interim data from its Phase Ib clinical study of XPro1595 in Alzheimer's disease. In addition, INmune
will host on July 14 a key opinion leader webinar in which the data will be discussed. The webinar will take place prior to
AAIC 2020, the world's largest and most influential international meeting dedicated to advancing dementia science. AAIC 2020
will run virtually July 27-31.
XPro1595 is a selective inhibitor of
soluble Tumor Necrosis Factor, a key inflammatory cytokine implicated in causing neuroinflammation in patients with Alzheimer's
disease. The Phase Ib multi-center, open-label, multi-dose study is currently enrolling patients with Alzheimer's disease
who express biomarkers of inflammation. The goal of the proof-of-biology trial is to determine if XPro1595 can reduce neuroinflammatory
biomarkers following 12 weeks of treatment. Results will inform the design of a proof-of-concept study using XPro1595 to treat
patients with Alzheimer's disease with biomarkers of inflammation. The study is supported by a $1M Part the Cloud Award from
the Alzheimer's Association.
The call will start with a brief presentation
of the data by RJ Tesi, M.D., CEO of INmune Bio, and CJ Barnum, Ph.D., Director of Neuroscience at INmune Bio, followed by a panel
discussion with the following participants:
KOL Discussion Call Information
To participate in this event, you must
register in advance. Please click on the link below. After registering, you will receive a confirmation email containing
information about joining the webinar.
To register and access the
live webinar click here
Time: 8:00 AM Eastern Time
XPro1595 is a next-generation inhibitor
of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF
(sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients
with Alzheimer's disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation
in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio's
About XPro1595 Clinical Trial
XPro1595 is currently being evaluated
in a Phase Ib clinical trial in Alzheimer's disease patients who have biomarkers of inflammation to determine if neutralizing
soluble TNF can decrease those biomarkers of neuroinflammation. There cannot be any assurance about the results of this trial.
Adults (>18 years old) diagnosed
with probable Alzheimer's disease defined by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's
Disease and Related Disorders Association criteria, confirmed with inflammatory biomarkers are being enrolled in this multicenter,
Phase Ib open-label study. The study will follow patients during a twelve-week period to determine the safety and the ability of
XPro1595 to reduce neuroinflammation using a combination of biomarkers of inflammation. The study will examine inflammatory and
disease-related biomarkers before treatment, at the halfway point, and at the end. Cognitive and neuropsychiatric symptoms will
be also be measured during the trial. The study will identify the dose of XPro1595 to be used in a larger Phase II disease modification
Clinical sites are located in Australia
and include KaRa MINDS in New South Wales, Central Adelaide Local Health Network in South Australia, Austin Health and Alfred Health
in Victoria, and The Australian Alzheimer's Research Foundation in Western Australia.
For additional clinical trial details,
About INmune Bio, Inc.
INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune
system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology
to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF
is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595), and
NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK
cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn
more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages
and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number
of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595, LIVNate ,
Quellor and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved
and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are
beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual
future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating
to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for
the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;
and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the
Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order
to reflect any event or circumstance that may arise after the date of this release.
David Moss, CFO (858) 964-3720
James Carbonara (646) 755-7412